Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimenMeghan C. Thompson, Anthony R. Mato, Joanna Rhodes et al.|Blood Advances|2022Cited by 57
Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United StatesAnuja Chatterjee, Matthew S. Davids, Sheila Shapouri et al.|Journal of Managed Care & Specialty Pharmacy|2021Cited by 20
Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United StatesSang Kyu Cho, Scott Johnson, Beenish S. Manzoor et al.|PharmacoEconomics|2020Cited by 19
Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International StudyMazyar Shadman, Anthony R. Mato, Beenish S. Manzoor et al.|Clinical Lymphoma Myeloma & Leukemia|2023Cited by 16
Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab in First-Line Chronic Lymphocytic Leukemia in the United StatesMatthew S. Davids, Michael Hallek, Anuja Chatterjee et al.|Blood|2019Cited by 11